Docoh
Loading...

55 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells. PCS3117 has received
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
or Commercialization of Compounds or Products by Processa, its Affiliates or Sublicensees, including all Third-Party Claims involving death or bodily injury caused
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
annual meeting to serve until their successors are duly elected or until their earlier death, resignation or removal. The individuals named as proxy … or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Our Board of Directors considers
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
of such annual meeting or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Our Board … to exercise the award or receive payment under the award after the participant’s death, (ii) transfer an award to a former spouse as required
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and providing evidence of its safety. “NL” means Necrobiosis Lipoidica, a rare chronic, and granulomatous disorder. “Osteonecrosis” means the death … tolerability issues or possibly even death. The observed potency and kinetics of our planned product candidates in preclinical studies may
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
Termination By Death or Disability. The Employee’s employment and rights to compensation under this Employment Agreement shall terminate if the Employee … is unable to perform the duties of his position due to death or disability lasting more than 90 days, and the Employee’s heirs, beneficiaries, successors
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
. “Osteonecrosis” means the death of bone cells due to decreased blood flow. It can lead to pain and collapse of areas of bone. ii PROSPECTUS SUMMARY This summary … , including, but not limited to, immunogenic responses, organ toxicities such as liver, heart or kidney or other tolerability issues or possibly even death
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
and providing evidence of its safety. “NL” means Necrobiosis Lipoidica, a chronic, disfiguring condition. “Osteonecrosis” means the death of bone … to, immunogenic responses, organ toxicities such as liver, heart or kidney or other tolerability issues or possibly even death. The observed potency and kinetics
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of its safety. “NL” means Necrobiosis Lipoidica, a chronic, disfiguring condition. “Osteonecrosis” means the death of bone cells due to decreased blood … such as liver, heart or kidney or other tolerability issues or possibly even death. The observed potency and kinetics of our planned product candidates
S-1/A
EX-10.4
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of the material terms of this Agreement. Termination by Death or Disability. The Employee’s employment and rights to compensation under this Employment … Agreement shall terminate if the Employee is unable to perform the duties of his position due to death or disability lasting more than 90 days
S-1/A
EX-3.2
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. Each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal. No decrease in the number … resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase
S-1/A
EX-10.5
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
to exercise the Award or receive payment under the Award after the Participant’s death; (b) transfer an Award to the former spouse of the Participant
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
Affiliates or Sublicensees, including all Third Party Claims involving death or bodily injury caused or allegedly caused by the use of such a Compound
S-1/A
EX-10.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
party who, in the event of the death of the Optionholder, shall thereafter be the beneficiary of an Option with the right to exercise the Option … that an Optionholder’s Continuous Service terminates (other than for Cause or upon the Optionholder’s death or Disability), the Optionholder may
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, including all Third Party Claims involving death or bodily injury caused or allegedly caused by the use of such a Compound or Product, and even
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
Affiliates or Sublicensees, including all Third Party Claims involving death or bodily injury caused or allegedly caused by the use of such a Compound
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
all Third Party Claims involving death or bodily injury caused or allegedly caused by the use of such a Compound or Product, and even
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
” means Necrobiosis Lipoidica, a chronic, disfiguring condition. “Osteonecrosis” means the death of bone cells due to decreased blood flow. It can … or kidney or other tolerability issues or possibly even death. The observed potency and kinetics of our planned product candidates in preclinical
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
Necrobiosis Lipoidica, a chronic, disfiguring condition. “Osteonecrosis” means the death of bone cells due to decreased blood flow. It can lead to pain … even death. The observed potency and kinetics of our planned product candidates in preclinical studies may not be observed in human clinical trials
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
Lipoidica, a chronic, disfiguring condition. “Osteonecrosis” means the death of bone cells due to decreased blood flow. It can lead to pain and collapse … , including, but not limited to, immunogenic responses, organ toxicities such as liver, heart or kidney or other tolerability issues or possibly even death